There are about 25435 clinical studies being (or have been) conducted in United Kingdom. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: - participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 - participants whose tumors express PD-L1 CPS ≥1 - all participants The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to: - EFS in participants whose tumors express PD-L1 CPS ≥10 - EFS in participants whose tumors express PD-L1 CPS ≥1 - EFS in all participants - OS in participants whose tumors express PD-L1 CPS ≥10 - OS in participants whose tumors express PD-L1 CPS ≥1 - OS in all participants
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Patients with MPS IIIA have a clinical disorder marked by severe and progressive brain disease and neurological symptoms due to the accumulation of undigested glycosaminoglycans in all cells of the body. This study will be the first in human clinical trial to explore the safety, tolerability and clinical efficacy of ex vivo gene therapy (autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene) in MPSIIIA patients. Following treatment with the gene therapy patients will be followed up for a minimum of 3 years.
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
The investigators aim to undertake a 49-month longitudinal study in a cohort of 360 healthy individuals of 60 years and older, living in East Anglia to understand the role of gut microbes (the microbiome) in healthy ageing. The investigators also aim to identify changes in the structure and function of the gut microbe populations that are associated with deteriorating mental health and cognitive function. Using clinically validated cognitive assessments and tests, study participants will be stratified in to one of three risk groups for developing dementia:- Cohort 1 - low (n=120). Cohort 2 - medium (n=120). Cohort 3 - high (n=120). Participants will be recruited from three streams - Primary Care, The NHS Bowel Cancer Screening Programme (BCSP) and the Norfolk & Suffolk Foundation Trust (NSFT). Following initial Telephone Contact and the Pre-Study Visit, all participants will be required to attend the Quadram Institute Clinical Research Facility (QI CRF) every 6 months over 4 years. At each of these follow-up visits, the participant will provide a stool sample (collected at home) and at differing time points, provide a blood sample and undergo a series of physical measurements, cognitive tests/questionnaires and complete a health questionnaire. All participants will undergo Optical Coherence Tomography scans at the Beccles & District War Memorial Hospital. There will be 2 subgroups in this study. Subgroup 1 - at least 30 participants from each cohort (n= at least 90) will undergo colonic tissue biopsies as part of routine clinical care using the NHS BCSP. Subgroup 2 - 30 participants from Cohort 3 will undergo brain imaging at the Norfolk & Norwich University Hospital (NNUH) Imaging Department. The results of the study will provide new insights into the gut-brain axis and the relationship between age-associated changes in gut microbe populations and declining mental health. Such insights will be of enormous value in developing new microbe-based strategies to improve lifelong health and wellbeing that impact on dementia development.
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: - Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). - Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR. - Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
This is a phase II prospective, interventional, open-labeled, proof-of-concept study. 2 years per participant, 2 years 6 months in total Total n=6 The primary objective is to assess the safety of human pancreatic islet transplantation into the ACE of participants with T1D. Safety analyses will involve examination of the incidence, severity, and type of treatment emergent AEs reported, and changes in vital signs, ophthalmic status and laboratory test results from baseline (Day 0 pre-transplantation) to specified time points throughout the study.
Acutely symptomatic abdominal wall hernia can cause many symptoms and complications. They can be associated with levels of morbidity beyond that seen in emergency laparotomy. There is limited data to guide practice in this field. This observational cohort study will explore variation in practice around assessment, repair and outcomes of hernias treated in the emergency setting.